HIGHLIGHTS
- who: Zhenzhen Zhai et al. from the School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, China have published the article: Clinical Research Progress of Small Molecule Compounds Targeting Nrf2 for Treating Inflammation-Related Diseases, in the Journal: Antioxidants 2022, 11, 1564. of /2022/
- what: 240 mg capsules (CinnaGen, Tehran, Iran) daily for 5 days All-cause mortality: For each pairwise comparison with the "no additional treatment" arm, the primary objective is to provide reliable estimates of the effect of study treatments on all-cause mortality. The study showed that the pharmacophore in semisynthetic pentacyclic triterpenoids is . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.